The findings of a new study on the Delta strain on August 4th caused concern. According to the official microblog of China Biopharmaceuticals (Sinopharm), the research team of China Biotech Yang Xiaoming of Sinopharm recently discovered that effective monoclonal antibodies against delta mutant strains have a neutralizing activity IC50 of up to 5ng/ml. This means that monoclonal antibodies are effective against mutated strains of coronavirus such as Delta, and the treatment of COVID pneumonia is expected to usher in specific drugs. At present, the clinical application of the antibody is progressing in an orderly manner, hoping to be used as soon as possible in the prevention and control of the COVID pandemic in China.
In addition, Kangtai Bio, a vaccine giant with a market value of more than 90 billion, has also received good news. It has successfully isolated multiple monoclonal strains of the COVID virus delta variant, preparing for the production of inactivated COVID vaccines against the delta variant.
The bigger catalyst for the vaccine sector comes from the latest bulletin of the American Academy of Infectious Diseases, which stated that the threshold for herd immunity has been raised to more than 80%, or even close to 90%, in the face of the need to expand the vaccination rate of the delta variant. The WHO previously stated that to achieve herd immunity, the vaccination rate must reach 70%. This means that the global demand for vaccines will likely increase further, which is undoubtedly good news for the vaccine sector. In addition, in order to increase the protection rate of vaccines, the need for a third booster shot of the vaccine is increasing.
The latest findings of the Sinopharm Group indicate that the 2B11 antibody has greater application value in the short-term prevention and early treatment of new coronary pneumonia caused by the Delta variant.
The neutralizing activity IC50 is as high as 5ng/ml, which means that the monoclonal antibody is effective against Delta and other COVID variants, and the treatment of COVID pneumonia is expected to usher in a specific drug. According to China Biotech, currently, the clinical application of the 2B11 antibody is progressing in an orderly manner, hoping to be used as soon as possible in the prevention and control of the COVID pandemic in China.
According to data, monoclonal antibodies, as targeted therapy drugs, have the characteristics of strong specificity, significant curative effect and low toxicity. They are known as “biological missiles”. Monoclonal antibodies with neutralizing effect can specifically neutralize viruses, to prevent the virus from entering the cell to proliferate, not only as short-term prevention for high-risk groups, but also for the treatment of diseases after virus infection.